Posts

AstraZeneca’s Camizestrant Misses Key First-Line Breast-Cancer Trial Goal

on

Ivonescimab Shows Survival Advantage Over Keytruda in Lung Cancer Trial

on

AbbVie’s T-cell engager shows survival benefit in Phase 3 multiple myeloma study

on

Ivonescimab’s Keytruda win raises the stakes for regulatory review and global adoption

on

Cullinan and Taiho Report Phase III Win for Zipalertinib–Chemotherapy Combo in First-Line EGFR Exon 20 Insertion–Mutant NSCLC

on

Merck advances sac-TMT/Keytruda combo in NSCLC as Keytruda patent cliff looms

on

Kura Reports Durable Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve ccRCC at KCRS 2026

on

Summit Touts Updated HARMONi Data Showing Consistent Survival Benefit for Ivonescimab in Western NSCLC Patients

on

Kelun's sac-TMT scores win in first-line PD-L1-negative NSCLC population missing from Merck's KEYTRUDA phase 3 program

on

ADC Therapeutics cuts 17% of staff after 27 patient deaths in Zynlonta trial

on

Despite 'decent' data, Verastem rethinks options for approved oncology combo in pancreatic cancer

on

Lilly’s Jaypirca scores another Phase III win in CLL, but use with Venclexta still evolving in practice

on

Lilly oncology chief went from extremely nervous to blown away by new Jaypirca CLL data

on

AstraZeneca's triplet combo (Imfinzi/Imjudo/lenvatinib) plus TACE helps a subset of liver cancer patients avoid progression

on

J&J's Erleada shows early wins in early prostate cancer but raises big questions for clinicians

on

ASCO: Merck, Kelun's sac-TMT ADC combo beats Keytruda by 65% on progression in first-line lung cancer

on

Can Revolution's miracle pancreatic cancer drug be topped? Immuneering, Actuate say yes – BioSpace, Stat News, and clinical trial updates, May 2026

on

Pfizer's Elrexfio Meets Phase III Primary Endpoint in Multiple Myeloma, Positioning Drug for Earlier-Line Use

on

Compass Therapeutics Stock Plummets After Mixed Trial Data in Biliary Tract Cancer Study

on

Compass Therapeutics (CMPX) Stock Declines as Tovecimig Trial Misses Overall Survival Endpoint Despite Strong PFS and ORR

on